Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 24, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - October 24, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/24/14 - "Methods of Administering Drugs in an Implantable Multi-Chamber Pump" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Gibson, Susan P.; Vanhove, Geertrui F., filed on March 27, 2014, was made available online on October 9, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Jazz Pharmaceuticals,
10/24/14 - AbbVie's HUMIRA adalimumab Receives U.S. FDA Approval for Extension of Polyarticular Juvenile Idiopathic Arthritis Indication to Patients Ages 2 and...
AbbVie's HUMIRA adalimumab Receives U.S. By a News Reporter-Staff News Editor at Health& Medicine Week AbbVie announced that the U.S. Food and Drug Administration has approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis to reducing signs and symptoms in patients ages 2 an
10/24/14 - Chinese Patent Medicine Market Trends Analysis and 2018 Forecasts
ReportsnReports.com adds Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018 market report to the pharmaceuticals category of its online industry research reports library. It analyses the policy environment, market scale, competition pattern, development trend and key enterprises in Chinese patent medicine...
10/24/14 - Covidien Announces U.S. Food and Drug Administration 510k Clearance for Nellcor? Portable SpO2 Patient Monitoring System
By a News Reporter-Staff News Editor at Health& Medicine Week Covidien plc announced U.S. Food and Drug Administration 510 clearance for the Nellcor? Portable SpO2 Patient Monitoring System. Part of a comprehensive Covidien respiratory function monitoring portfolio, this convenient, handheld patient monitor is simple to use and ideal for fast,
10/24/14 - Cydex Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Oct. 24 Cydex Pharmaceuticals, Lenexa, Kansas, has been assigned a patent developed by six co-inventors for "formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use." The co-inventors are Karen T. Johnson, Lawrence, Kansas, Rebecca L. Wedel, Lawrence, Kansas, Stephen G. Machatha, Overland Park, Ka
10/24/14 - Icahn School of Medicine at Mount Sinai opens genomics research facility in Branford [New Haven Register, Conn.]
Oct. 24 BRANFORD Connecticut's reputation as a center for biomedical research received a boost Thursday with an announcement that the Icahn School of Medicine at Mount Sinai has opened a state-of-the-art genomics research facility on Commercial Street. "We are investing in industry leaders like the Icahn School of Medicine at Mount Sinai so th
10/24/14 - Pacira Pharmaceuticals Reports Data Supporting Safety of EXPAREL in Peripheral Nerve Block [Manufacturing Close - Up]
Pacira Pharmaceuticals reported data demonstrating that EXPAREL used in peripheral nerve blocks has comparable safety to placebo and bupivacaine HCl. According to a release from the Company, the analysis, based on a review of six Phase 1-3 clinical trials, will be presented during a podium session at the annual meeting of the American Society of...
10/24/14 - Phosplatin Therapeutics: 1st Patients Enrolled in Phase I First-in- Human Clinical Trial in Solid Tumors [Manufacturing Close - Up]
The clinical study is expected to enroll up to 80 patients across three sites: The University of Texas MD Anderson Cancer Center in Houston, Texas; the Sarah Cannon Research Institute in Nashville, Tennessee; and the University of Colorado Cancer Center in Aurora, Colorado, the company noted in a release. According to Principal Investigator Daniel
10/24/14 - Wellness Uprising Offers Safe, Natural, Effective Solutions for Today's Health Concerns
Wellness Uprising is dedicated to the thesis that every living organism on this planet had the ability to enjoy perfect health- long before the big chemical and drug companies lobbied their way into the controls of the FDA and EPA. Pell believes that, contrary to drug company ads, using your body in the way it was designed is the best way to pay th
10/23/14 - Acceleron Collaboration Partner Celgene to Present Data at the American Society of Nephrology Kidney Week 2014
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that its collaboration partner, Celgene, and investigators on the sotatercept program will present preclinical and interim clinical data at the...
10/23/14 - Actavis Says US Appeals Court Upholds Patent Of Lo Loestrin Fe
DUBLIN- Irish specialty pharmaceutical company Actavis plc Thursday confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling on its birth control pill Lo Loestrin Fe. Earlier in January, US District court of New Jersey has found United States Patent No. 7,704,984 to be valid and infringed by Lupin...
10/23/14 - Aduro Presents Updated Interim Results from Phase 1b Clinical Trial in Mesothelioma at International Mesothelioma Interest Group Conference
Aduro BioTech, Inc., a leader in cancer immunotherapy, today announced the presentation of updated safety and efficacy data from an ongoing Phase 1 b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma. The results were presented by Raffit Hassan, M
10/23/14 - Alimera Sciences to Release Third Quarter 2014 Results
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will release its third quarter of fiscal year 2014 financial results after the market close on Thursday, November 6, 2014. About Alimera Sciences, Inc. Alimera Sci
10/23/14 - American Red Cross to Participate in Cerus' IDE Study to Address Chikungunya and Dengue Blood Safety Risks
Cerus Corporation today announced that the American Red Cross will participate in Cerus clinical protocol to make the INTERCEPT Blood System for platelets available under an Expanded Access Investigational Device Exemption to regions in the United States with outbreaks of chikungunya and dengue virus. "In Puerto Rico, dengue viruses have been p
10/23/14 - Amgen: BiTE Immunotherapy Blinatumomab Secures FDA Priority Review Designation [Professional Services Close - Up]
Amgen reported that that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for the investigational bispecific T cell engager antibody construct, blinatumomab. Amgen said that a Marketing Authorization Application has also been submitted to the European Medicines Agency via the centralized procedure for.
10/23/14 - Arbor Pharmaceuticals Announces FDA Approval of Sotylize?
Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved its New Drug Application for Sotylize oral solution. It is such a common practice that the FDA changed the tablet labeling to include instructions for pharmacists on how to compound a simple syrup based sotalol suspension. Ed Schutter, President& CEO of
10/23/14 - Arno Therapeutics to Present Encouraging Data From Ongoing Phase I/II Trial Evaluating Onapristone in CRPC at 21st Annual PCF Scientific Retreat
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it will present data from its ongoing Phase I/II clinical trial evaluating investigational lead compound onapristone in men with advanced castration-resistant prostate cancer after failure of abiraterone or
10/23/14 - Ashland increasing pharmaceutical technologies capabilities to address global drug development and bioavailability enhancement trends
Release date- 22102014- WILMINGTON, Del.- On September 30, Ashland Specialty Ingredients, a commercial unit of Ashland Inc., opened a state-of-the-art pharmaceutical center of excellence in Wilmington. One way of accomplishing this is by investing in leading-edge facilities and laboratories,' said Luis Fernandez-Moreno, president, Ashland Specialty
10/23/14 - Celator Pharmaceuticals Announces Pricing Of A $12.9M Public Offering Of Common Stock And Warrants To Purchase Common Stock
Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the pricing of an underwritten public offering of 6,611,150 shares of common stock and warrants to purchase up to 661,115 shares of its common stock. Roth Capital Partners and National Securities Corporation are actin
10/23/14 - Celator(R) Pharmaceuticals Announces Pricing of a $12.9 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the pricing of an underwritten public offering of 6,611,150 shares of common stock and warrants to purchase up to 661,115 shares of its common stock. Roth Capital Partners and National Securities Corporation are act
10/23/14 - Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications, is pleased to announce positive top-line results for its Phase 2 b randomized double-blind study comparing three dosing regimens of Brilacidin to daptomycin for the treatment of Acute Bacterial...
10/23/14 - CHI's Latest Report Shows Modest Improvement in FDA Medical Device Review Times
Working with the FDA, CHI examined a number of issues that directly impact medical device approvals, such as decision efficiency, process efficiency and outcomes, while also providing context on legislative regulations governing FDA medical device product review processes and procedures. "The FDA is a critical linchpin in the medical technology...
10/23/14 - Clinical Trial to Evaluate Two Biothera Cancer Drugs for Advanced Pancreatic Cancer
A phase 1 b clinical trial at the University of Illinois at Chicago will evaluate a new combination therapy for advanced pancreatic cancer that includes two Biothera cancer immunotherapy drug candidates. The investigator-sponsored study combines Biothera s Imprime PGG and mucin-1 targeted monoclonal antibody BTH1704 with the chemotherapy...
10/23/14 - Cross Pollinate Ideas and Watch Innovations Flower
The Center for Trends and Technology, sponsored for the second year by Rockwell Automation (TM) and its Partner Network Program, will be a center for cross pollinating ideas at PACK EXPO International and Pharma EXPO. "It's a concept that has been top of mind as we prepare for PACK EXPO International and Pharma EXPO 2014," he adds. The sessions an
10/23/14 - Dexcom Secures FDA Approval for Dexcom SHARE [Manufacturing Close - Up]
Dexcom has received U.S. Food and Drug Administration approval for its CGM remote mobile communications device: Dexcom SHARE. According to a release from the company, Dexcom SHARE, an accessory to the Dexcom G4 PLATINUM Continuous Glucose Monitoring System, uses a secure wireless connection to transmit the glucose levels of a person with diabetes t
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415